CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ALPMY

Androgen deprivation therapy (ADT)

Phase 3
Astellas Pharma (ALPMY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metastatic Hormone Sensitive Prostate Cancer

View Full Landscape
Drug Information

Target Indication

Metastatic Hormone Sensitive Prostate Cancer

Clinical Trial

NCT04076059

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.